Sachs Associates’ Post

Modiblast Pharma GmbH is ready to advance into the clinical development phase with novel Dendritic Cell Therapies for liquid cancers. The focus is to target the core issue in acute myeloid leukemias (AML) and Myelodysplastic Syndromes (MDS): the extremely high rate of relapses after successful initial therapy. The Modiblast approach (3 patents granted) combines immunomodulators to induce blast cells to differentiate into leukemia-specific dendritic cells (DCleu) in the patient. This triggers both innate and adaptive immune cells in blood and tissue to kill remaining or recurring blasts and generates memory cells. Contrary to e.g. CAR-T there is no need to identify and select specific target molecules. And it doesn’t require complicated and expensive ex vivo cell extraction and preparation procedures and GMP facilities. Our long-term goal is to provide an easy-to-use self-administered drug that can stabilize remissions or halt progression of the diseases. This therapy may also normalize thrombocyte/neutrophil counts. The next step of clinical development is a Phase 1a/2b study which recently has passed BfArM scientific advice. Meet Modiblast Pharma GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

⚕️ BPGbio, Inc.'s NAi Interrogative Biology platform has been advancing precision medicine throughout 2024 ⚕️ In 2024, BPGbio, Inc. made significant strides in redefining #medicine through its #biology-first, #AI-powered platform. The NAi Interrogative Biology® platform continued to demonstrate its impact, supporting late-stage #clilnicaltrials for #oncology and #rarediseases, including #glioblastoma, #pancreaticcancer, and #sarcopenia. Notably, the Phase 2a trial of BPM31510IV for pancreatic cancer revealed promising early indications of clinical benefit, emphasizing hope for those impacted by one of the deadliest forms of #cancer. NAi derived #drugtargets and #biomarkers are being investigated as possible #treatments for #HuntingtonsDisease and #Alzheimers. Further NAi #discoveries have led to #FDA Rare Pediatric Disease Designation for Potential Treatment of #PrimaryCoQ10Deficiency as well as FDA Rare Pediatric Disease Designation for Investigational Treatment for #EpidermolysisBullosa. All in all, these and many other #breakthroughs and discoveries have led to an astounding 2024 in terms of advancing precision medicine. Through #partnerships, #collaborations, and #investment, NAi is discovering targets and biomarkers, de-risking clinical trials and finding new applications for already vetted #therapeutics. Partner with us on your drug discovery & development journey! For more information about the NAi Platform, please visit: https://lnkd.in/gvTXPEEf #NAiInterrogativeBiology #venturecapital #privateequity #drugdevelopment #drugdiscovery #mitochondrialmedicine #biopharma #biotech #artificialintelligence #neurology #quinomics

🔍 Exciting news in biotech investments! These investments show the growing potential in biometrics. Great to see advancements across different health areas, from mental health to cancer treatment 🇺🇸 Spyre Therapeutics | $180 million PIPE | monoclonal antibodies | preclinical in inflammatory bowel disease 🇺🇸 Engrail Therapeutics | $157 million series B | precision neuroscience | phase 2 in generalized anxiety disorder 🇨🇦 Cybin Inc | $150 million PIPE | mental healthcare | phase 2 in major depressive disorder 🇩🇪 Tubulis GmbH | €128 million ($138.75 million) series B2 | antibody drug conjugates | preclinical in multiple solid tumors 🇺🇸 Unicycive Therapeutics | $50 million PIPE | kidney disease treatments | phase 1 in hyperphosphatemia 🇬🇧 Relation | $35 million seed | multi omics for drug discovery | discovery in osteoporosis 🇸🇪 Asgard Therapeutics | €30 million ($32.53 million) series A | cancer immunotherapies | preclinical in cancer 🇬🇧 Mission Therapeutics | £25.2 million ($32 million) | deubiquitylating enzyme inhibitors | phase 2 in cardiac surgery-associated kidney injury 🇺🇸 Elicio Therapeutics | $6 million PIPE | immunotherapies | phase 2 in pancreatic ductal adenocarcinoma

# Only put off until tomorrow what you are willing to die having left undone ## Seize the Opportunity with Sonnet BioTherapeutics' SON-1010 for Tumor Treatment! 💪🚀 Sonnet BioTherapeutics Holdings, Inc. has just released groundbreaking research data on their leading drug candidate, SON-1010, in the renowned journal Frontiers in Immunology. This exceptional drug employs a fully human albumin-binding construct, showcasing its potential as a powerful weapon in the fight against tumors. With its mechanism, patent claims, and ongoing clinical trials now detailed in this publication, the future looks incredibly promising for SON-1010. As an investment advisor passionate about healthcare and investing, I urge you to take advantage of this thrilling opportunity to invest in Sonnet BioTherapeutics. By incorporating SON-1010 into your Health Savings Account \(HSA\) portfolio, you not only contribute to the advancement of tumor treatment but also harness the potential for significant financial growth. Act now to avoid the Fear of Missing Out \(FOMO\) on this revolutionary healthcare breakthrough! #hsa #investing #healthcare #health #family #wellness 💰💼🏥🌍👨👩👧👦✨

PulseSight Therapeutics, launched early 2024, is an ophthalmology clinical-stage biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology for AMD. PulseSight has developed a proprietary platform that uses a user-friendly electro-transfection system to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle to treat eye diseases. The company’s lead program PST-611 in GA is ready to enter the clinic by the end of 2024, whilst its second program, PST-809 in wet AMD is at the very late stage of preclinical IND-enabling studies. Both first-in-class candidates benefit from a solid preclinical package showing their ability to address multiple pathological pathways involved in these two forms of AMD, thus providing a higher efficacy compared to current treatments.  First clinical trials have been performed (PST-606 in non-infectious uveitis), showing the very good safety profile of both the plasmid and the delivery procedure as well as the long lasting expression of the therapeutic proteins, allowing to significantly reduce the frequency of injections (4 to 6 months). Pulsesight Therapeutics is managed by a highly experienced executive team and board of Directors; it is financed with seed investment from leading venture capital investors Dominik Escher, PhD, founding partner of Pureos Bioventures and Kostas Kaloulis, PhD, Venture Partner at ND Capital. Meet PulseSight Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

Roca Therapeutics is a biotech start-up headquartered in Nice, France, with a groundbreaking ophthalmology program. Our lead candidate, RCT002, is less than 18 months from IND/CTA submission and has shown promising pharmacological data. Developed for topical administration, RCT002 offers a unique pharmaco-economic profile. It complements the current standard of care administered via intravitreal injections (meaning no direct competition), potentially modifying the disease by blocking resistant angiogenesis, oxidative stress, inflammation, and fibrosis. RCT002 is backed by solid translational and mechanistic data. We have designed a robust disease, clinical, and regulatory strategy targeting Radiation-induced Maculopathy (an orphan niche market for accelerated approval) and Diabetic Macular Edema (upside market opportunity). Roca Therapeutics has already secured a international VC (3B Future) for the seed financing who is now looking to co-lead the current Series A funding round to develop RCT002 until the end of Phase 2a (and extend the pipeline). We believe RCT002 represents a compelling investment opportunity. Meet Roca Therapeutics @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

NLC Health Ventures is launching DiaphOne Therapeutics — a biotech company transforming treatment for diabetic complications, neurodegeneration and other diseases. DiaphOne Therapeutics, founded by NLC Health Ventures, will be developing first-in-class small molecule RAGE antagonists that target the intracellular RAGE-DIAPH1 pathway. These compounds show efficacy in halting the progression of debilitating conditions like diabetic complications, ALS, Alzheimer’s Disease and breast cancer. Built on the groundbreaking research of Dr. Ann Marie Schmidt (NYU Langone Health in collaboration with NYU Technology Opportunities & Ventures) and Dr. Alexander Shekhtman (University at Albany, State University of New York), the company is currently completing in vivo proof-of-concept studies. With NLC’s backing, DiaphOne will progress to lead optimization, advancing its path toward clinical development. Read more about DiaphOne Therapeutics in the press release below. #lifesciences  #Biotech #therapeutics #diabetes #neurodegeneration #breastcancer #translationalresearch #NLC

🔍 ALS Treatment Clinical Trials Update 🔍  Here are highlighted developments in ALS from early 2024. 1. NurOwn's Advanced Trials (March 2024): Brainstorm is moving forward with a Phase 3b trial of its cell therapy, NurOwn, which has shown potential benefits in earlier trials for patients with mild-to-moderate ALS. This next phase aims to confirm its efficacy and safety. https://lnkd.in/ezMVPCxP 2. Pridopidine's Global Trial Preparation (January 2024): Prilenia Therapeutics is gearing up for a pivotal global Phase 3 trial for pridopidine, targeting the sigma-1 receptor to potentially slow ALS progression by improving cellular functions and reducing stress. https://lnkd.in/eG_zURnc 3. Prosetin's Clinical Progress (March 2024): ProJenX has received FDA clearance to resume dosing ALS patients in their Phase 1 trial of prosetin, a promising kinase inhibitor intended to protect motor neurons. https://lnkd.in/eGCWbxNQ 4. Masitinib Awaits Approval (January 2024): AB Science’s masitinib is under review for marketing authorisation in Europe, with a decision expected Q2. This treatment aims to reduce immune cell activity that drives ALS progression, showing promise, particularly in patients with mild to moderate symptoms. https://lnkd.in/eHhNYvhP #ALSResearch #ClinicalTrials #Neuroscience #Biotech 📧 Need expert medical writing or research help? For details on our services or a project quote, contact us at https://lnkd.in/eUd9SdiB

𝙀𝙢𝙚𝙧𝙜𝙞𝙣𝙜 𝙏𝙧𝙚𝙣𝙙𝙨 𝙞𝙣 𝙩𝙝𝙚 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 𝙎𝙚𝙘𝙪𝙧𝙚 𝙖 𝙁𝙍𝙀𝙀 𝙎𝙖𝙢𝙥𝙡𝙚: https://lnkd.in/g6QwVu9V The 𝘽𝙧𝙖𝙞𝙣 𝙏𝙪𝙢𝙤𝙧 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙞𝙨 & 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘𝙨 𝙈𝙖𝙧𝙠𝙚𝙩 is experiencing dynamic growth, fueled by advancements in medical technology and a deeper understanding of neuro-oncology. As we navigate through 2024, several key trends are shaping the landscape: 𝙄𝙣𝙣𝙤𝙫𝙖𝙩𝙞𝙫𝙚 𝘿𝙞𝙖𝙜𝙣𝙤𝙨𝙩𝙞𝙘 𝙏𝙤𝙤𝙡𝙨: Cutting-edge imaging technologies, such as advanced MRI and PET scans, are revolutionizing the early detection of brain tumors. These tools enhance accuracy, allowing for timely intervention and improved patient outcomes. 𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 𝙏𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨 & 𝙋𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙈𝙚𝙙𝙞𝙘𝙞𝙣𝙚: The shift towards personalized medicine is leading to the development of targeted therapies that address specific genetic mutations and molecular characteristics of brain tumors. This approach is significantly improving treatment efficacy and minimizing side effects. 𝙄𝙢𝙢𝙪𝙣𝙤𝙩𝙝𝙚𝙧𝙖𝙥𝙮 & 𝙉𝙤𝙫𝙚𝙡 𝙏𝙧𝙚𝙖𝙩𝙢𝙚𝙣𝙩𝙨: Emerging therapies, including immunotherapy and gene editing techniques, are showing promise in treating brain tumors that were previously considered resistant to conventional methods. These innovative treatments offer new hope for patients. 𝙆𝙚𝙮 𝙋𝙡𝙖𝙮𝙚𝙧𝙨: The brain tumor diagnosis & therapeutics industry comprises of various key market players such as Pfizer, Amgen, AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Karyopharm Therapeutics Inc., Canon Medical Systems Corporation, Lantern Pharma Inc. (Nasdaq: LTRN), and others. 𝘼𝙘𝙘𝙚𝙨𝙨 𝙁𝙪𝙡𝙡 𝙍𝙚𝙥𝙤𝙧𝙩: https://lnkd.in/gGz6zwUT As we move forward, collaboration between researchers, clinicians, and industry leaders will be crucial in advancing treatments and improving patient care. Let’s continue to support innovation and drive progress in this vital field! #braintumor #neurooncology #medicalinnovation #healthcare #precisionmedicine #immunotherapy #markettrends #marketresearch #globalindustry